Targeted-therapy in advanced renal cell carcinoma

Current Medicinal Chemistry

Volumn 18, Issue 11, 2011, Pages 1651-1657

  Pirrotta, M T ^a   Bernardeschi, P ^a   Fiorentini, G ^a  

^a SAN GIUSEPPE HOSPITAL   (Italy)

Author keywords

Advanced; Metastatic; RCC; Renal cell carcinoma; Targeted therapy; TKI

Indexed keywords

ALPHA INTERFERON; AXITINIB; BEVACIZUMAB; EVEROLIMUS; MAMMALIAN TARGET OF RAPAMYCIN; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMSIROLIMUS; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTHENIA; BONE MARROW SUPPRESSION; CARDIOTOXICITY; CLEAR CELL CARCINOMA; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG MECHANISM; DRUG RESPONSE; DRUG STRUCTURE; DRUG TARGETING; ENZYME INHIBITION; FATIGUE; HAND FOOT SYNDROME; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERTENSION; HYPOTHYROIDISM; KIDNEY CARCINOMA; NEPHRECTOMY; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; STOMATITIS; THROMBOTIC THROMBOCYTOPENIC PURPURA;

CARCINOMA, RENAL CELL; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASM METASTASIS; TOR SERINE-THREONINE KINASES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79955689582     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986711795471293     Document Type: Article

References (47)

1. Rini, B.I.; Campbell, S.C.; Escudier, B. Renal cell carcinoma. Lancet, 2009, 373, 1119-1132.
2. Lam, J.S.; Breda, A.; Belldegrun, A.S.; Figlin, R.A. Evolving principles of surgical management and prognostic factors for outcome in renal cell carcinoma. J. Clin. Oncol. 2006, 35, 5565-5575. (Pubitemid 46631337)
3. Pagoda, A.; Petrylak, D.; Thompson, S. Cytotoxic chemotherapy for advanced renal cell carcinoma. Urol. Clin. North. Amer. 1993, 20, 303-321. (Pubitemid 23154480)
4. Parton, M.; Gore, M.; Eisen, T. Role of cytokine therapy in 2006 and beyond for metastatic renal cell cancer. J. Clin. Oncol. 2006, 24, 5584-5592. (Pubitemid 46631339)
5. Tamaskar, I.; Pili. R. Update on novel agents in renal cell carcinoma. Expert. Rev. Anticancer Ther. 2009, 9(12), 1817-1827.
6. Robinson, D.R.; Wu, Y.; Lin, S. The protein tyrosine kinase family f the human genome. Oncogene, 2000, 19, 5548-5557.
7. Furge, K.A.; MacKeigan, J.P.; The, B.T. Kinase targets in renal-cell carcinomas: reassessing the old and discovering the new. Lancet Oncol. 2010, April 8 [e-pub ahead of print].
8. George, D.J.; Kaelin Jr, W.G. The von Hippel Lindau protein, vascular endothelial growth factor, and kidney cancer. N. Engl. J. Med. 2003, 349, 419-421. (Pubitemid 36910018)
9. McDermott, D.F.; George, D.J. Bevacizumab as a treatment option in advanced renal cell carcinoma: an analysis and interpretation of clinical trial data. Cancer Treat. Rev. 2010, 36, 216-223.
10. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, C.M.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med. 2007,356, 115-124. (Pubitemid 46089672)
11. Escudier, B.; Eisen, T.; Stadler, W.M.; Szczylik, C.; Oudard, S.; Siebels, M.; Negrier, S.; Chevreau, C.; Solska, E.; Desai, A.A.; Rolland, F.; Demkow, T.; Hutson, T.E.; Gore, M.; Freeman, S.; Schwartz, B.; Shan, M.; Simantov, R.; Bukowski, R.M. Sorafenib in advanced clear-cell renal cell carcinoma. N. Engl. J. Med. 2007, 356, 125-134. (Pubitemid 46089673)
12. Escudier, B.; Pluzanska, A.; Koralewski, P.; Ravaud, A.; Bracarda, S.; Szczylik, C.; Chevreau, C.; Filipek, M.; Melichar, B.; Bajetta, E.; Gorbunova, V.; Bay, J.O.; Bodrogi, I.; Jagiello-Gruszfeld, A.; Moore, N. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma : a randomised, double-blind phase III trial. Lancet, 2007, 370, 2103-2111. (Pubitemid 350296300)
13. Yang, J.C.; Howort, L.; Sherry, R.; et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N. Engl. J. Med. 2003,349, 427-434. (Pubitemid 36910021)
14. Mekhail, T.M.; Abou-Jawde, R.M.; Bou-Merhi, G.; et al. Validation and extension of the Memorial Sloan-Kettering prognostic factors model for survival in patients with previously untreated metastitic renal cell carcinoma. J. Clin. Oncol. 2005, 23, 832-841. (Pubitemid 46224183)
15. Mizutani, Y. Recent advances in molecular targeted therapy for metastatic renal cell carcinoma. Int. J. Urol. 2009, 16, 444-448.
16. Escudier, B.; Bellmunt, J.; Negrier, S.; Bajetta, E.; Melichar, B.; Bracarda, S.; Ravaud, A.; Golding, S.; Jethwa, S.; Sneller, V. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J. Clin. Oncol. 2010, 28, 2137-2143.
17. Rini, B.I.; Halabi, S.; Rosenberg, J.E.; Stadler, W.M.; Vaena, D.A.; Archer, L.; Atkins, J.N.; Picus, J.; Czaykowski, P.; Dutcher,J.; Small, E.J. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J. Clin. Oncol., 2010, 28, 2137-2143.
18. Lowinger, T.B.; Riedl, B.; Dumas, J.; Smith, R.A. Design and discovery of small molecules targeting raf-1 kinase. Curr. Pharm. Des. 2002, 8, 2269-2278. (Pubitemid 35189900)
19. Wilhelm, S.; Chien, D.S. BAY 43-9006: preclinical data. Curr. Pharm. Des. 2002, 8, 2255-2257. (Pubitemid 35189898)
20. Stein, M.N.; Flaherty, K.T. Sorafenib and sunitinib in renal cell carcinoma. Clin. Cancer Res. 2007, 13, 3765-3770. (Pubitemid 47037579)
21. Escudier, B.; Szczylik, C.; Hutson, T.E.; Demkow, T.; Staehler, M.; Rolland, F.; Negrier, S.; Laferriere, N.; Scheuring, U.J.; Cella, D.; Shah, S.; Bukowski, R.M. Randomized phase II trial of first-line treatment with sorafenib versus interferon alfa-2a in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 2009, 27, 1280-1289.
22. Mendel, D.B.; Laird, A.D.; Xin, X.; Louie, S.G.; Christensen, J.G.; Li, G.; Schreck, R.E.; Abrams, T.J.; Ngai, T.J.; Lee, L.B.; Murray, L.J.; Carver, J.; Chan, E.; Moss, K.G.; Haznedar, J.O.; Sukbuntherng, J.; Blake, R.A.; Sun, L.; Tang, C.; Miller, T.; Shirazian, S.; McMahon, G.; Cherrington, J.M. In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting VEGF and PDGF receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin. Cancer Res. 2003, 9, 327-337. (Pubitemid 36109749)
23. Izzedine, H.; Billemont, B.; Thibault, F.; Rixe, O. New challenges in kidney cancer therapy: sunitinib. Annals of Oncol. 2007, 18, ix83-6.
24. Faivre, S.; Delbaldo, C.; Vera, K.; Robert, C.; Lozahic, S.; Lassau, N.; Bello, C.; Deprimo, S.; Brega, N.; Massimini, G.; Armand, J.P.; Scigalla, P.; Raymond, E. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patirnts with cancer. J. Clin. Oncol., 2006, 24, 25-35. (Pubitemid 46630490)
25. Motzer, R.J.; Rini, B.I.; Bukowski, R.M.; Curti, B.D.; George, D.J.; Hudes, G.R.; redman, B.G.; Margolin, K.A.; Merchan, J.R.; Wilding, G.; Ginsberg, M.S.; Bacik, J.; Kim, S.T.; Baum, C.M.; Michaelson, M.D. Sunitinib in patients with metastatic renal cell carcinoma. JAMA, 2006, 295, 2516-2524. (Pubitemid 43854967)
26. Motzer, R.J.; Michaelson, M.D.; Redman, B.G.; Hudes, G.R.; Wilding, G.; Figlin, R.A.; Ginsberg, M.S.; Kim, S.T.; Baum, C.M.; DePrimo, S.E.; Li, J.Z.; Bello, C.L.; Theuer, C.P.; George, D.J.; Rini, B.I. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet derived growth factor receptor, in patients with metastatic renal cell carcinoma. J. Clin. Oncol., 2006, 24, 16-24. (Pubitemid 46630489)
27. Motzer, R.J.; Hutson, T.E.; Tomczak, P.; Michaelson, M.D.; Bukowski, R.M.; Rixe, O.; Oudard, S.; Negrier, S.; Szczylik, C.; Kim, S.T.; Chen, I.; Bycott, P.W.; Baum, P.W.; Figlin, R.A. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 115-124. (Pubitemid 46089672)
28. Figlin, R.A.; Hutson, T.E.; Tomczak, P.; Michaelson, R.M.; Bukowski, R.M.; Nègrier, S.; Huang, X.; Kim, S.T.; Chen, I.; Motzer, R.J. Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment ofmetastatic renal cell carcinoma (mRCC). J. Clin. Oncol., 2008, 26, May 20 suppl; abstr 5024).
29. Gore, M.E.; Szczylik, C.; Porta, C.; Bracarda, S.; Bjarnason, G.A.; Oudard, S.; Hariharan, S.; Lee, S.H.; Haanen, J.; Castellano, D.; Vrdoljak, E.; Schoffski, P.; Mainwaring, P.; Nieto, A.; Yuan, J.; Bukowski, R. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol., 2009, 10, 757-763.
30. Sablin, M.P.; Bouaita, L.; Balleyguier, C.; et al. Sequential use of sorafenib and sunitinib: retrospective analysis in 90 patients. J. Clin. Oncol., 2007, 25, S244.
31. Dham, A.; Dudek, A.Z. Sequential therapy with sorafenib and sunitinib in renal cell carcinoma. J. Clin. Oncol., 2007, 25, S261.
32. Rixe, O.; Bukowski, R.M.; Michaelson, M.D.; Wilding, G.; Hudes, G.R.; Bolte, O.; Motzer, R.J.; Bycott, P.; Liau, K.F.; Freddo, J.; Trask, P.C.; Kim, S.; Rini, B.I. Axitinib treatment in patients with cytokine-refractory metastatic renal cell cancer: a phase II study. Lancet Oncol., 2007, 8, 975-984. (Pubitemid 47629888)
33. Rini, B.I.; Widing, G.T.; Hudes, W.M.; et al. Axitinib (AG-013736; AG) in patients with metastatic renal cell cancer (RCC) refractory to sorafenib. J. Clin. Oncol., 2007, 25, S242.
34. Sternberg, C.N.; Davis, I.D.; Mardiak, J.; Szczylik, C.; Lee, E.; Wagstaff, J.; Barrios, C.H.; Salman, P.; Gladkov, O.A.; Kavina, A.; Zarbà, J.J.; Chen, M.; McCann, L.; Pandite, L.; Roychowdhury, D.F.; Hawkins, R.E. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J. Clin. Oncol., 2010, 28, 1061-1068.
35. LaPlant, K.D.; Louzon, P.D. Pazopanib: an oral multitargeted tyrosine kinase inhibitor for use in renal cell carcinoma. Ann. Pharmacother., 2010, 44, 1054-1060.
36. Gore, M.E. Temsirolimus in the treatment of advanced renal cell carcinoma. Ann. Oncol., 2007, 18 (Suppl. 9), ix87-88.
37. Hudes, G.R. Targeting mTOR in renal cell carcinoma. Cancer, 2009, 115, 2313-2320.
38. Hudes, G.; Carducci, M.; Tomczak, P.; Dutcher, J.; Figlin, R.; Kapoor, A.; Staroslawska, E.; Sosman, J.; McDermott, D.; Bodrogi, I.; Kovacevic, Z.; Lesovoy, V.; Schmidt-Wolf, I.G.; Barbarash, O.; Gokmen, E.; O'Toole, T.; Lustgarten, S.; Moore, L.; Motzer, R.J. Temsirolimus, interferon alpha, or both for advanced renal-cell carcinoma. N. Engl. J. Med., 2007, 356, 2271-2281. (Pubitemid 46849157)
39. Amato, R.J.; Jac, J.; Giessinger, S.; Saxena, S.; Willis, J.P. A phase 2 study with a daily regimen of the oral mTOR inhibitor RAD001 (everolimus) in patients with metastatic clear cell renal cell cancer. Cancer, 2009, 115, 2438-2446.
40. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Urbanowitz, G.; Berg, W.J.; Kay, A.; Lebwohl, D.; Ravaud, A. Efficacy of everolimus in advanced renal cell carcinoma : a double-blind, randomised, placebocontrolled phase III trial. Lancet, 2008, 372, 449-456.
41. Motzer, R.J.; Escudier, B.; Oudard, S.; Hutson, T.E.; Porta, C.; Bracarda, S.; Grunwald, V.; Thompson, J.A.; Figlin, R.A.; Hollaender, N.; Kay, A.; Ravaud, A. Phase III trial of everolimus for metastatic renal cell carcinoma: final results and analysis of prognostic factors. Cancer, 2010, Jun 14 [Epub ahead of print].
42. Hutson, T.E.; Bukowski, R.M.; Cowey, C.L.; Figlin, R.; Escudier, B.; Sternberg, C.N. Sequential use of targeted agents in the treatment of renal cell carcinoma. Crit. Rev. Oncol. Hematol., 2010, Aug 11. [Epub ahead of print].
43. Sosman, J.; Puzanov, I. Combination targeted therapy in advanced renal cell carcinoma. Cancer, 2009,115 (10 Suppl) , 2368-2375.
44. Biswas, S.; Kelly, J.; Eisen, T. Cytoreductive nephrectomy in metastatic clear-cell renal cell carcinoma: perspectives in the tyrosine kinase inhibitor era. The Oncologist, 2009, 14, 52-59.
45. A clinical trial comparing efficacy and safety of sunitinib versus placebo for the treatment of patients at high risk of recurrent renal cell cancer (S-TRAC). http://www.clinicaltrial.gov/ct2/results?term=s-trac (Accessed November 17, 2010).
46. Sorafenib in treating patients at risk of relapse after undergoing surgery to remove kidney cancer. http://www.clinicaltrial.gov/ct2/show/ NCT00492258? term=sorce&rank=2 (Accessed November 17, 2010).
47. Sunitinib or sorafenib in treating patients with kidney cancer that was removed by surgery. http://www.clinicaltrial.gov/ct2/show/NCT00326898? term=assure&rank=5 (Accessed November 17, 2010).